Abstract:9584 Background: Lung carcinomas are most often diagnosed at stage IV, with metastases, which contribute to 90% of deaths of patients. Enormous efforts have been made in previous studies in seek of underlying mechanisms and treatments that prevent or cure metastases. However, few comprehensive conclusions have been drawn on organ-specific genomic landscapes and molecular dependencies of lung cancer metastases, largely due to limited sample sizes. Methods: We employed massive targeted next generation sequencing (NGS) with a panel covering 425 cancer-related genes on 10409 samples from 8619 patients with lung cancer, including 8479 from primary tumors and 1930 from metastases to the brain, liver, pleura, bones, and lymph nodes. We investigated single nucleotide variants (SNVs), copy number variants (CNVs), structural variations (SVs), mutational signatures, and other genomic characteristics at all primary and metastatic sites. With data of primary-metastatic tumor pairs, we also examined genomic evolutionary patterns. Results: Our data revealed that metastases harbored more instable and complicated genomes. Most SNVs (5/6), CNVs (41/47), and SVs (2/3) that showed significant differences of prevalence between primary tumors (PTs) and metastases (MTs) were MT-enriched. Among them, we identified a novel MT-enriched event, PTK2 amplification (2.33 folds), as well as known ones including mutations of TP53, ARID1A, and BRCA1 (1.23, 1.74, and 2.29 folds) , and amplifications of MYC, RICTOR, and EGFR (2.04, 2.15, and 1.59 folds). In addition, almost all actionable CNV alterations (6/7) showed higher frequencies in MTs. ALK fusions and EGFR mutations, which indicate distinct target therapies, exhibited opposite preference in MTs and PTs, respectively. We also identified MT site-specificity of alterations, such as NF2, TSC2, and LRP1B mutations enriched in the brain, BRAF and GNAS mutations absent in the liver, and APOBEC-associated mutational signatures enriched in lymph nodes. Moreover, we unraveled organ-specific patterns of genomic evolutionary trajectories in metastatic diseases. Conclusions: The genomic profile and evolutionary pattern of metastatic lung cancer differed from that of primary tumors. The identification of site-specific characteristics that may have empowered directional metastasis, such as NF2, TSC2, and LRP1B mutations in the brain and APOBEC-associated mutational signatures in lymph nodes, may guide personalized disease management, design of clinical trials, and/or discovery of therapeutic targets for metastatic lung cancer at different body regions.

The mechanism investigation of mutation genes in liver and lung metastasis of colorectal cancer by using NGS technique

Delineating the Underlying Molecular Mechanisms and Key Genes Involved in Metastasis of Colorectal Cancer Via Bioinformatics Analysis

Comprehensive Mutation Profiling of Colorectal Cancer Patients With Lung or Liver Metastasis by Targeted Next-Generation Sequencing

Molecular mechanisms investigation for liver metastasis of colorectal cancer by combined bioinformatic gene expression profile analysis

Whole-Exome Sequencing Characterized the Landscape of Somatic Mutations and Pathways in Colorectal Cancer Liver Metastasis

Prognostic Impact Of Mutation Profiling In Chinese Patients With Colorectal Liver Metastases.

Integrated analysis of genes associated with poor prognosis of patients with colorectal cancer liver metastasis

Proteogenomic Characterization and Comprehensive Integrative Genomic Analysis of Human Colorectal Cancer Liver Metastasis

Identification of Candidate Biomarkers Correlated With the Pathogenesis and Prognosis of Non-small Cell Lung Cancer via Integrated Bioinformatics Analysis

Proteome analysis and tissue microarray for profiling protein markers associated with lymph node metastasis in colorectal cancer.

Genetic characteristics of isolated lung metastasis and isolated liver metastasis from colorectal cancer

A Gene Mutation-Based Risk Model for Prognostic Prediction in Liver Metastases

Genetic Differences Between Lung Metastases and Liver Metastases from Left-Sided Microsatellite Stable Colorectal Cancer: Next Generation Sequencing and Clinical Implications

Characterization of Genomic Alterations in Colorectal Liver Metastasis and Their Prognostic Value

Identification of Liver Metastasis-Associated Genes in Human Colon Carcinoma by Mrna Profiling

Comprehensive genomic profiling reveals prognostic signatures and insights into the molecular landscape of colorectal cancer

Correlation between NGS panel-based mutation results and clinical information in colorectal cancer patients

Single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer tumors

Genomic Characterization of Metastatic Lung Cancers.

Multi gene mutation signatures in colorectal cancer patients: predict for the diagnosis, pathological classification, staging and prognosis

A Cohort Study on the Molecular Mechanism of Distinct Therapeutic Effects and Prognosis in Chinese Colorectal Cancer Patients Who Underwent Neoadjuvant or Surgical Therapies.